Nexcelom Bioscience Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Nexcelom Bioscience's estimated annual revenue is currently $19.1M per year.(i)
  • Nexcelom Bioscience received $Undisclosed in venture funding in March 2018.
  • Nexcelom Bioscience's estimated revenue per employee is $155,000

Employee Data

  • Nexcelom Bioscience has 123 Employees.(i)
  • Nexcelom Bioscience grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Nexcelom Bioscience is a developer and marketer of image cytometry products for cell analysis in life science and biomedical research. Products range from cell viability counters (Cellometer) to high throughput microwell image cytometry workstations (Celigo), used in thousands of research laboratories in academic institutes, and pharmaceutical and biotech companies. The company contributes to the life science industry through innovation and expertise in the science of cell counting. The product family includes instruments, consumables and reagents. Nexcelom customers engage in a wide variety of research, such as cancer research, immunology, stem cell research, and neuroscience. Nexcelom offers different Cellometer models to count and analyze cell lines and primary cells, through bright field and fluorescence imaging modes. In addition, Celigo is a powerful high image quality, high throughput image cytometry system for adherent and suspension cells in microwell plates. Nexcelom Bioscience is a fast-growing company in a huge market. With its headquarters and manufacturing facilities in the Boston area, the company currently has over 80 global employees, who are fast-paced, customer-centric, helpful to colleagues and customers, and passionate about their impact in life science.

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Nexcelom Bioscience News

2018-03-20 - Ampersand Invests in Nexcelom Bioscience

Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growt ...

09/03/2019 - Hemoglobinopathies Market : Type, Insights Reports With ...

Hemoglobinopathies Market : Type, Insights Reports With Danaher, Nexcelom Bioscience, Abbott, Bio-Rad Laboratories, NIHON KOHDEN, ...

09/08/2019 - Bench Top Automatic Cell Sorter Market Industry SWOT Analysis to 2024 Top Companies: LW Scientific, Bio-Rad Laboratories, Nexcelom Bioscience, Becton Dickinson

... Automatic Cell Sorter Market Industry SWOT Analysis to 2024 Top Companies: LW Scientific, Bio-Rad Laboratories, Nexcelom Bioscience, ...

09/03/2019 - Know the Current and Future Growth of Automatic Cell Sorter ...

Some of key competitors or manufacturers included in the study are: , LW Scientific, Bio-Rad Laboratories, Nexcelom Bioscience, Becton ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Nexcelom Bioscience Funding

DateAmountRoundLead InvestorsReference
2018-03-21$UndisclosedUndisclosedAmpersand Capital PartnersArticle